📣 VC round data is live. Check it out!

Meditera Valuation Multiples

Discover revenue and EBITDA valuation multiples for Meditera and similar public comparables like Bactiguard, Pentixapharm Holding, Creo Medical Group, Daxor and more.

Meditera Overview

About Meditera

MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.


Founded

1996

HQ

Turkey

Employees

N/A

Financials (FY)

Revenue: $63M
EBITDA: $5M

EV

$51M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Meditera Financials

Meditera reported last fiscal year revenue of $63M and EBITDA of $5M.

In the same fiscal year, Meditera generated $19M in gross profit, $5M in EBITDA, and had net loss of ($203K).

Revenue (LTM)


Meditera P&L

In the most recent fiscal year, Meditera reported revenue of $63M and EBITDA of $5M.

Meditera is unprofitable as of last fiscal year, with gross margin of 30%, EBITDA margin of 7%, and net margin of (0%).

See analyst estimates for Meditera
Last FY202320242025202620272028
Revenue$63M$32M$46M$63M
Gross Profit$19M$14M$18M$19M
Gross Margin30%44%40%30%
EBITDA$5M$4M$5M$5M
EBITDA Margin7%11%11%7%
EBIT Margin4%18%12%4%
Net Profit($203K)$566K$2M($203K)
Net Margin(0%)2%4%(0%)

Financial data powered by Morningstar, Inc.

Meditera Stock Performance

Meditera has current market cap of $61M, and enterprise value of $51M.

Market Cap Evolution


Meditera's stock price is $0.64.

Meditera share price decreased by 2.8% in the last 30 days, and by 4.4% in the last year.

See more trading valuation data for Meditera
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$51M$61M3.8%-2.8%0.7%-4.4%$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Meditera Valuation Multiples

Meditera trades at 0.8x EV/Revenue multiple, and 11.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Meditera

EV / Revenue (LTM)


Meditera Financial Valuation Multiples

As of May 23, 2026, Meditera has market cap of $61M and EV of $51M.

Meditera has a P/E ratio of (300.6x).

Last FY202320242025202620272028
EV/Revenue0.8x1.6x1.1x0.8x
EV/EBITDA11.3x14.6x10.0x11.3x
EV/EBIT20.4x8.8x9.5x20.4x
EV/Gross Profit2.7x3.6x2.8x2.7x
P/En/m107.8x38.0xn/m
EV/FCF9.6xn/m5.9x9.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Meditera Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Meditera Margins & Growth Rates

Meditera grew revenue by 26% and EBITDA by 137% in the last fiscal year.

In the most recent fiscal year, Meditera reported gross margin of 30%, EBITDA margin of 7%, and net margin of (0%).

See estimated margins and future growth rates for Meditera

Meditera Margins

Last FY202420252026202720282029
Gross Margin30%40%30%
EBITDA Margin7%11%7%14%
EBIT Margin4%12%4%
Net Margin(0%)4%(0%)(0%)
FCF Margin8%19%8%

Meditera Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth26%44%37%26%
Gross Profit Growth29%6%
EBITDA Growth137%46%(12%)137%
EBIT Growth(8%)(53%)
Net Profit Growth72%184%(113%)72%
FCF Growth(9263%)(38%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Meditera Operational KPIs

Meditera's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Meditera's Rule of X is 79% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Meditera
Last FY202320242025202620272028
Rule of 4040%
Bessemer Rule of X79%
S&M Expenses to Revenue3%3%4%3%
G&A Expenses to Revenue6%5%5%6%
R&D Expenses to Revenue1%1%1%1%
Opex to Revenue26%26%28%26%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Meditera Competitors

Meditera competitors include Bactiguard, Pentixapharm Holding, Creo Medical Group, Daxor, SMAIO, BATM Advanced Communications, SciBase Holding, Klea, Pulmonx and Cyclopharm.

Most Meditera public comparables operate across Medical Devices, Medical Supplies, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Bactiguard3.0x3.1x15.1x18.5x
Pentixapharm Holding524.9x(3.1x)
Creo Medical Group7.7x4.2x(1.4x)(2.4x)
Daxor6.1x7.2x
SMAIO5.3x4.7x(55.3x)(56.6x)
BATM Advanced Communications0.4x0.5x2.6x3.9x
SciBase Holding11.9x9.6x(5.9x)(6.4x)
Klea3.4x14.9x

This data is available for Pro users. Sign up to see all Meditera competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Meditera

When was Meditera founded?Meditera was founded in 1996.
Where is Meditera headquartered?Meditera is headquartered in Turkey.
Is Meditera publicly listed?Yes, Meditera is a public company listed on Borsa Istanbul.
What is the stock symbol of Meditera?Meditera trades under MEDTR ticker.
When did Meditera go public?Meditera went public in 2021.
Who are competitors of Meditera?Meditera main competitors include Bactiguard, Pentixapharm Holding, Creo Medical Group, Daxor, SMAIO, BATM Advanced Communications, SciBase Holding, Klea, Pulmonx, Cyclopharm.
What is the current market cap of Meditera?Meditera's current market cap is $61M.
What is the current revenue of Meditera?Meditera's last fiscal year revenue is $63M.
What is the current revenue growth of Meditera?Meditera revenue growth (vs. last FY) is 26%.
What is the current EV/Revenue multiple of Meditera?Current revenue multiple of Meditera is 0.8x.
Is Meditera profitable?No, Meditera is not profitable.
How many companies Meditera has acquired to date?Meditera hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Meditera has invested to date?Meditera hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Meditera

Lists including Meditera

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial